TrialNature medicine2022

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.

Andreas Hagen Røssevold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.